Close Menu

NEW YORK (360Dx) – Roche on Friday said that its PD-L1 assay has received CE-label expansion to identify untreated and previously treated patients with metastatic non-small cell lung cancer that are eligible for Merck's Keytruda (pembrolizumab) immunotherapy.

As a result, the Ventana PD-L1 (SP263) Assay — the only fully automated PD-L1 test for use with Keytruda to launch on Roche's BenchMark series of instruments — is available in countries accepting the CE mark, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.